BioMarin Reports 20% Revenue Growth to $989.7 Million in Q2 2026

BioMarin Pharmaceutical Inc. reported significant financial results for the second quarter of 2026, with total revenues reaching $989.7 million, a 20% increase from $825.4 million in the same period of 2025. For the first half of 2026, revenues totaled $1.76 billion, compared to $1.57 billion in the prior year, marking a 12% increase. The company's net product revenues were $984.4 million for the quarter, up from $813.0 million a year earlier, driven by the acquisition of Amicus Therapeutics and increased sales of existing products. However, net income fell sharply to $44.8 million, down from $240.5 million in Q2 2025, reflecting higher operating expenses and interest costs associated with the acquisition financing.

The financial performance was impacted by a substantial rise in operating expenses, which totaled $878.8 million for the quarter, compared to $548.5 million in the previous year. This increase was primarily due to higher costs in research and development, selling, general and administrative expenses, and significant amortization of intangible assets acquired from Amicus. The company reported a net loss of $91.9 million from Amicus since the acquisition date, contributing to the overall decline in profitability.

Strategically, BioMarin completed the acquisition of Amicus Therapeutics on April 27, 2026, for approximately $5.3 billion. This acquisition is expected to enhance BioMarin's portfolio with two new treatments for lysosomal storage diseases and U.S. rights to a potential first-in-class oral CCR2 inhibitor for focal segmental glomerulosclerosis. The integration of Amicus is anticipated to yield synergies, although it has also led to restructuring charges and increased operational costs.

Operationally, BioMarin's product adoption rates have shown positive trends, particularly with VOXZOGO, which saw increased sales volume from new patients. The company reported a total of 940,854 in net product revenues from the U.S. market, with significant contributions from Europe and Latin America. The company’s employee headcount has also increased as a result of the acquisition, reflecting the integration of Amicus's workforce.

Looking ahead, BioMarin remains focused on leveraging its expanded product portfolio and pipeline to drive future growth. The company is actively monitoring macroeconomic conditions that could impact its operations, including inflation and currency fluctuations. BioMarin anticipates that cash generated from its commercial products, along with its cash reserves and financing options, will be sufficient to meet its liquidity needs over the next 12 months. The company is also preparing for upcoming regulatory submissions and potential product approvals, which could further enhance its market position.